Literature DB >> 25843685

p70 S6-kinase mediates the cooperation between Akt1 and Mek1 pathways in fibroblast-mediated extracellular matrix remodeling.

Anna Goc1, Harika Sabbineni1, Maha Abdalla1, Payaningal R Somanath2.   

Abstract

Previous studies have demonstrated both synergistic and opposing effects of Akt and Mek1/2 in various cell functions and disease states. Furthermore, Akt has been reported to inhibit and activate cRaf/Mek pathway, suggesting that their mutual interaction and cooperation may be cell type, stimuli and/or context specific. While PI3-kinase/Akt and cRaf/Mek pathways have been implicated in the regulation of extracellular matrix (ECM) remodeling, mutual interactions between these two pathways and their specific contributions to the events leading to ECM synthesis and assembly is not clear. We investigated the specific role of Akt1 and Mek1 in ECM synthesis and assembly by NIH 3T3 fibroblasts and how these effects were reconciled to mediate overall ECM remodeling. Our study identified that cooperation between Akt1 and Mek1 is necessary to mediate ECM synthesis. Whereas Akt1 activation resulted in Mek1 activation as evidenced by increased ERK1/2 phosphorylation, Mek1 inhibition using U0126 or DN-Mek1 resulted in enhanced Akt1 phosphorylation. Interestingly, both Akt1 and Mek1 activities were needed for the synthesis and assembly of ECM. The effect of Akt1 and Mek1 on ECM synthesis was reconciled through the activation of p70 S6-kinase via phosphorylation at T421/S424 and S411, respectively. Furthermore, Akt1 and Mek1 cooperated in mediating ECM assembly via activation of integrin β1. Together, we show for the first time that Akt1 and Mek1 pathways cooperate in the regulation of ECM remodeling by the fibroblasts.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Akt1; Extracellular matrix; Integrin; Mek1; mTOR; p70 S6-kinase

Mesh:

Substances:

Year:  2015        PMID: 25843685      PMCID: PMC4428983          DOI: 10.1016/j.bbamcr.2015.03.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  40 in total

Review 1.  Matricellular proteins: extracellular modulators of cell function.

Authors:  Paul Bornstein; E Helene Sage
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

Review 2.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

3.  The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1.

Authors:  M M Chou; J Blenis
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

4.  Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.

Authors:  Y Tang; Z Chen; D Ambrose; J Liu; J B Gibbs; J Chernoff; J Field
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

5.  Raf-MEK-Erk cascade in anoikis is controlled by Rac1 and Cdc42 via Akt.

Authors:  O Zugasti; W Rul; P Roux; C Peyssonnaux; A Eychene; T F Franke; P Fort; U Hibner
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

6.  Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt.

Authors:  S Eguchi; H Iwasaki; H Ueno; G D Frank; E D Motley; K Eguchi; F Marumo; Y Hirata; T Inagami
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

7.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.

Authors:  Wen-Lin An; Richard F Cowburn; Lin Li; Heiko Braak; Irina Alafuzoff; Khalid Iqbal; Inge-Grundke Iqbal; Bengt Winblad; Jin-Jing Pei
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt.

Authors:  P R Somanath; J Vijai; J V Kichina; T Byzova; E S Kandel
Journal:  Oncogene       Date:  2009-05-04       Impact factor: 9.867

9.  Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.

Authors:  Donglei Zhang; Menashe Bar-Eli; Sylvain Meloche; Pnina Brodt
Journal:  J Biol Chem       Date:  2004-03-01       Impact factor: 5.157

10.  Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis.

Authors:  Diviya Sinha; Saswati Bannergee; John H Schwartz; Wilfred Lieberthal; Jerrold S Levine
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

View more
  4 in total

1.  ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.

Authors:  I A Khan; B H Yoo; O Masson; S Baron; D Corkery; G Dellaire; L D Attardi; K V Rosen
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

2.  Pharmacological inhibition of β-catenin prevents EndMT in vitro and vascular remodeling in vivo resulting from endothelial Akt1 suppression.

Authors:  Harika Sabbineni; Arti Verma; Sandeep Artham; Daniel Anderson; Oge Amaka; Fang Liu; Subhadra P Narayanan; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2019-04-13       Impact factor: 5.858

3.  Distinct effects of pharmacological inhibition of stromelysin1 on endothelial-to-mesenchymal transition and myofibroblast differentiation.

Authors:  Ahlam Alharthi; Arti Verma; Harika Sabbineni; Mir S Adil; Payaningal R Somanath
Journal:  J Cell Physiol       Date:  2020-12-15       Impact factor: 6.513

4.  IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.

Authors:  Qing Wang; Yan Zhang; Jiang Zhu; Honggang Zheng; Shuntai Chen; Li Chen; Hsin-Sheng Yang
Journal:  Signal Transduct Target Ther       Date:  2020-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.